Key result
Rivaroxaban plus aspirin links to ~62% lower VTE risk vs rivaroxaban alone in long-term IVCF patients.
Why the study?
Long-term indwelling inferior vena cava filters increase thrombotic risk, and single-channel anticoagulation remains inadequate for preventing thrombotic events.
Does rivaroxaban combined with aspirin reduce the incidence of combined venous thromboembolism in patients with long-term inferior vena cava filter implantation compared to rivaroxaban alone?
Cohort (n=119)
Yes
Does rivaroxaban combined with aspirin reduce the incidence of combined venous thromboembolism in patients with long-term inferior vena cava filter implantation compared to rivaroxaban alone?
Hazard Ratio: 0.38 (95% CI 0.14–0.98)
Absolute Event Rate: 9.8% vs 24.1%
p-value: p=0.037
In patients with long-term inferior vena cava filters, adding aspirin to rivaroxaban significantly reduced combined venous thromboembolism at 12 months without increasing bleeding risk compared to rivaroxaban alone.
May reduce combined VTE in long-term IVCF patients; hypothesis-generating and requires randomized confirmation.
BackgroundInferior vena cava filter (IVCF) is used to prevent pulmonary embolism (PE) due to deep vein thrombosis (DVT), and some filters are indwelling for a long time, which increase the risk of thrombotic events. Single-channel anticoagulation is still inadequate in the prevention of thrombosis. This study aims to explore the efficacy and safety of rivaroxaban combined with aspirin versus rivaroxaban alone in the prevention of thrombotic events in patients with long-term IVCF implantation.MethodsA retrospective analysis was conducted on patients with long-term IVCF implantation in the two centers from August 2021 to October 2024. Among them, 58 cases were in the single-channel (SC) group, who only took rivaroxaban orally after surgery, and 61 cases were in the dual-channel (DC) group, who took rivaroxaban and aspirin orally after surgery. The follow-up period was 12 months. The primary endpoint was the incidence of combined venous thromboembolism (VTE). The secondary endpoints were the recurrence rate of lower extremity DVT, the incidence of IVCF thrombosis (IVCFT), PE, and adverse events, Venous Clinical Severity Score (VCSS) and Chronic Venous Insufficiency Questionnaire (CIVIQ-20).ResultsThe incidence of combined VTE in Group SC (14/58, 24.1%) was higher than that in Group DC (6/61, 9.8%) (HR: 0.38, 95% CI: 0.14-0.98, P=0.037). The incidence of IVCFT, VCSS and CIVIQ-20 at 12 months in Group SC were higher than those in Group DC. There were no significant differences in the incidence of DVT recurrence, PE, bleeding-related adverse events, and all-cause mortality between the two groups.ConclusionFor patients with long-term IVCF implantation, compared with rivaroxaban alone, the dual-channel inhibition of rivaroxaban combined with aspirin may reduce the occurrence of thrombotic events, alleviate clinical symptoms and improve the quality of life of patients, without increasing the risk of adverse events such as bleeding.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Long-term inferior vena cava filter (IVCF) implantation (n=119). Rivaroxaban combined with aspirin vs. Rivaroxaban alone was evaluated on Incidence of combined venous thromboembolism (VTE) (HR 0.38, 95% CI 0.14-0.98, p=0.037). Rivaroxaban combined with aspirin reduced the incidence of combined venous thromboembolism compared to rivaroxaban alone in patients with long-term IVCF implantation (9.8% vs 24.1%; HR 0.38; P=0.037).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: